The city of Sugar Land is helping support the expansion of Hope Biosciences, a Sugar Land-based biopharmaceutical company specializing in adult stem cell-based therapeutics, city officials announced in a Jan. 7 news release.

Zooming in

The $1 million performance-based incentive comes after the Sugar Land-based business purchased a permanent building in the city at 16700 Creek Bend Drive, per the release. The company will invest $2 million into improving the building and create 15 new jobs, averaging a $61,240 salary, in the next five years.

The incentive—distributed $200,000 annually over five years—will be provided through the Sugar Land Office of Economic Development & Tourism, according to the release.



“Hope Biosciences is a homegrown success story and a key example of how life science companies can thrive in Sugar Land,” Jennifer Alexander, Sugar Land business development manager, said in the release. “This incentive marks the first granted to a life sciences company and signals our commitment to supporting this sector, which is critical to our city’s economic future.”

Diving in deeper

Hope Biosciences develops therapies using stem cells from a patient’s own body to regenerate or repair damaged tissues and treat conditions such as neurodegenerative and autoimmune diseases. It is the only company in the United States to offer clinical-grade stem cell banking for adults and newborns, per the release.

According to the release, the company—which partners with regional and national institutions and provides direct-to-consumer stem cell banking services—is advancing clinical trials for diseases including:
  • Multiple sclerosis
  • Lupus
  • Traumatic brain injury
“Use of Hope Biosciences’ technology continues to grow significantly, but it all started here,” Hope Biosciences CEO Donna Chang said in the release. “The city has supported us at every stage, and their continued commitment reinforces our deeply held belief that Sugar Land is the ideal place to grow a company like ours.”